Navigation Links
SpectraScience CEO Jim Hitchin Featured in Interview With The Wall Street Transcript
Date:5/6/2009

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical device company, today announced that The Wall Street Transcript has published an in-depth interview with Chief Executive Officer Jim Hitchin. The interview, in its entirety, is available on the company's website at http://www.spectrascience.com/tinymce/jscripts/tiny_mce/plugins/ajaxfilemanager/uploaded/Wall%20Street%20Transcript.pdf

Mr. Hitchin said, "Each year there are literally hundreds of thousands of cases of colorectal, cervical and esophageal cancer which, because they are not diagnosed or caught early enough, result in higher mortality rates and higher costs. Our technology enables physicians to more accurately diagnose these diseases, and to do so at an earlier stage. This is critical to reducing deaths from cancer and to reducing overall costs to the healthcare system."

SpectraScience's technology provides the healthcare community with the promise of a higher degree of objectivity and sensitivity in the cancer screening process for colon cancer and cervical cancer. It is also undergoing clinical trials for an esophageal cancer screening application.

During the interview, Mr. Hitchin also reiterated that the company is focusing all resources in sales, adding that it has a competitive advantage from a technology standpoint and that there are no direct competitors to its cancer screening platforms. He emphasized that the chance to detect cancers early, or much earlier than is currently the case, means more people are going to live longer.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

    Contact:
    SpectraScience, Inc.                     Investor Relations
    Jim Hitchin, Chief Executive Officer     Hayden Communications
    (858) 847-0200  x 201                    Todd Pitcher
                                             (858)-518-1387

                                             Media Relations
                                             Gitenstein & Assadi PR
                                             Susan Assadi
                                             (800) 922-8792


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
2. SpectraScience Strengthens Leadership Team With Four Key Hires
3. Jim Dorst Joins SpectraScience as CFO
4. SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors
5. Bio-Matrix Scientific Group Featured as Stock Pick in Oakleys Column on WallStreetCorner.com
6. Histogen Featured on Economic Report Television Series
7. Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal
8. Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference
9. BOXX Personal Supercomputer for Research Scientists Featured at SC08
10. ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting
11. Former Speaker of the House Newt Gingrich Featured Wednesday
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will ... AC0010 at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria ... I/II clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring ...
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom Healthcare ( ... hospitals, will present its chain-of-custody solution for tracking and securing medications at booth ... Dec. 4-8, 2016. , Aerocom has a proven solution for tracking medications via ...
(Date:12/2/2016)... ... 2016 , ... The Conference Forum has announced that the 3rd annual ... on February 1-3, 2017 at the Roosevelt Hotel in New York City. Led by ... unique 360-degree approach, which addresses the most up-to-date information regarding business aspects, clinical advancements ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, ... on their recent FDA Class II 510(k) clearance for their flagship medical device, ... commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies ...
Breaking Biology Technology:
(Date:11/17/2016)... 2016 Global Market Watch: Primarily supported ... Population-Based Banks and Academics) market is to witness a value ... shows the highest Compounded Annual Growth Rate (CAGR) of 10.75% ... the analysis period 2014-2020. North America ... by Europe at 9.56% respectively. ...
(Date:11/15/2016)... Nov. 15, 2016  Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...
(Date:11/14/2016)... , Nov. 14, 2016  Based ... identification market, Frost & Sullivan recognizes FST ... Sullivan Award for Visionary Innovation Leadership. FST ... the biometric identification market by pioneering In ... solution for instant, seamless, and non-invasive verification. ...
Breaking Biology News(10 mins):